Lluita contra la Sida Foundation, HIV Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Antimicrob Agents Chemother. 2010 Jul;54(7):3047-8. doi: 10.1128/AAC.00363-10. Epub 2010 May 3.
Little is known about raltegravir removal by hemodialysis in patients with end-stage renal disease (ESRD). We therefore measured raltegravir concentrations in plasma in pre- and postdialyzer blood samples from 2 ESRD HIV-infected patients. The hemodialysis extraction ratio and raltegravir hemodialysis clearance were 5.5% and 9.1 ml/min in patient 1 and 9.5% and 19.1 ml/min in patient 2, respectively. Our results suggest minimal raltegravir removal by hemodialysis with no specific raltegravir dosage adjustments required in HIV-infected patients undergoing hemodialysis.
对于终末期肾病（ESRD）患者，血液透析清除拉替拉韦的情况知之甚少。因此，我们测量了 2 例 ESRD 合并 HIV 感染患者透析前和透析器后血液样本中的拉替拉韦浓度。患者 1 的血液透析提取率和拉替拉韦血液透析清除率分别为 5.5%和 9.1ml/min，患者 2 分别为 9.5%和 19.1ml/min。结果表明，血液透析对拉替拉韦的清除作用很小，无需对接受血液透析的 HIV 感染患者进行拉替拉韦特殊剂量调整。
